Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Yunjiao Zhou; Zezhong Liu; Shibo Li; Wei Xu; Qianqian Zhang; Israel T Silva; Cheng Li; Yanling Wu; Qingling Jiang; Zhenmi Liu; Qiujing Wang; Yu Guo; Jianbo Wu; Chengjian Gu; Xia Cai; Di Qu; Christian T Mayer; Xiangxi Wang; Shibo Jiang; Tianlei Ying; Zhenghong Yuan; Youhua Xie; Yumei Wen; Lu Lu; Qiao Wang

doi:10.1016/j.celrep.2021.108699

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Cell Rep. 2021 Feb 2;34(5):108699. doi: 10.1016/j.celrep.2021.108699. Epub 2021 Jan 12.

Authors

Yunjiao Zhou¹, Zezhong Liu², Shibo Li³, Wei Xu¹, Qianqian Zhang¹, Israel T Silva⁴, Cheng Li¹, Yanling Wu¹, Qingling Jiang⁵, Zhenmi Liu⁵, Qiujing Wang³, Yu Guo⁶, Jianbo Wu¹, Chengjian Gu¹, Xia Cai¹, Di Qu¹, Christian T Mayer⁷, Xiangxi Wang⁸, Shibo Jiang¹, Tianlei Ying¹, Zhenghong Yuan⁹, Youhua Xie¹⁰, Yumei Wen¹¹, Lu Lu¹², Qiao Wang¹³

Affiliations

¹ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Biosafety Level 3 Laboratory, Shanghai Medical College, Fudan University, Shanghai 200032, China.
² Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Biosafety Level 3 Laboratory, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: zzliu17@fudan.edu.cn.
³ Department of Infectious Disease, Zhoushan Hospital, Wenzhou Medical University, Zhoushan 316021, China.
⁴ Laboratory of Bioinformatics and Computational Biology, A. C. Camargo Cancer Center, São Paulo 01509-010, Brazil.
⁵ West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China.
⁶ State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin 300350, China.
⁷ Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
⁸ CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
⁹ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Biosafety Level 3 Laboratory, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: zhyuan@shmu.edu.cn.
¹⁰ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Biosafety Level 3 Laboratory, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: yhxie@fudan.edu.cn.
¹¹ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Biosafety Level 3 Laboratory, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: ymwen@shmu.edu.cn.
¹² Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Biosafety Level 3 Laboratory, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: lul@fudan.edu.cn.
¹³ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Biosafety Level 3 Laboratory, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address: wangqiao@fudan.edu.cn.

Abstract

Several potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus have been identified. However, antibody-dependent enhancement (ADE) has not been comprehensively studied for SARS-CoV-2, and the relationship between enhancing versus neutralizing activities and antibody epitopes remains unknown. Here, we select a convalescent individual with potent IgG neutralizing activity and characterize his antibody response. Monoclonal antibodies isolated from memory B cells target four groups of five non-overlapping receptor-binding domain (RBD) epitopes. Antibodies to one group of these RBD epitopes mediate ADE of entry in Raji cells via an Fcγ receptor-dependent mechanism. In contrast, antibodies targeting two other distinct epitope groups neutralize SARS-CoV-2 without ADE, while antibodies against the fourth epitope group are poorly neutralizing. One antibody, XG014, potently cross-neutralizes SARS-CoV-2 variants, as well as SARS-CoV-1, with respective IC₅₀ (50% inhibitory concentration) values as low as 5.1 and 23.7 ng/mL, while not exhibiting ADE. Therefore, neutralization and ADE of human SARS-CoV-2 antibodies correlate with non-overlapping RBD epitopes.

Keywords: SARS-CoV-1; SARS-CoV-2; antibody-dependent enhancement; neutralizing activity; receptor-binding domain epitope.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antibodies, Monoclonal / immunology
Antibodies, Neutralizing / immunology*
Antibodies, Viral / immunology*
Antibodies, Viral / therapeutic use
Antibody-Dependent Enhancement*
Antigen-Antibody Reactions
COVID-19 / immunology
COVID-19 / virology
COVID-19 Drug Treatment
Cell Line
Child
Cluster Analysis
Epitopes / immunology*
Female
Humans
Inhibitory Concentration 50
Male
Middle Aged
Protein Domains / immunology
SARS-CoV-2 / isolation & purification
Spike Glycoprotein, Coronavirus / chemistry
Spike Glycoprotein, Coronavirus / immunology
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
Epitopes
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2